Abstract: The present invention relates to a gene of swine vesicular disease virus (SVDV) and the mutant strains of the gene, and the expression plasmids, the preparation process thereof. The invention also relates to a vaccine for use in the prophylaxis of swine vesicular disease composition containing the mutant strains. Furthermore, the invention provides a process for differentiating mutant strains of SVDV from the wild type strain of SVDV, coxsackievirus and foot-and-mouth disease virus by polymerase chain reaction.

Abstract: Disclosed is a new Streptomyces candidus strain, and relevant uses thereof.

Abstract: Disclosed is a controlled release tacrine dosage form, which comprises: (a) a core; (b) an inner active layer comprising tacrine and a binder; (c) a release-controlling layer comprising one or more release-controlling-film-forming polymer; and (d) an active overcoat comprising tacrine and a binder. Also disclosed is a process for preparing the controlled release dosage form.

Abstract: The present invention teaches method for culturing nematode pesticidal compositions, to produce at a high yield, and generate biotic compositions that are effective as insecticides with high pesticidal activity and preventive effects.

Abstract: The present invention provides a genetically recombinant xylanase with high yield and good activity, and a process for the production of the recombinant xylanase. The present invention also provides the coding sequence of the recombinant sequence, vectors bearing the coding sequence and the transformants containing the vectors. The present invention further provide a column wherein the recombinant xylanase is immobilized.

Abstract: Disclosed are novel 1,2,4-triazin-5-one biphenyl derivatives having structural formula (I) useful as non-peptide antagonists of angiotensin II receptor: ##STR1## where R.sub.1 represents alkyl, cycloalkyl, or substituted or unsubstituted aryl;R.sub.2 represents alkyl, substituted or unsubstituted aryl, or arylalkyl;A and D independently represent C--R.sub.3, N, NH or C.dbd.O, wherein when A and D independently denote C--R.sub.3 or N, b and c are independently a double bond, and when A and D independently denote NH or C.dbd.O, b and c are independently a single bond; provided that b and c are not both double bonds; andR.sub.3 is hydrogen, dialkylphosphonate or halogen;and pharmaceutically acceptable salts thereof.Also disclosed is the use of the compounds of formula (I) as non-peptide antagonists of angiotensin II receptor, in the treatment of cardiovascular diseases, in particular hypertension and congestive heart failure.

Abstract: The invention provides a novel catalase which is cloned from Bacillus theremoglucosidasius. The invention further provides a process for preparing catalase in high yield, which comprises constructing expression vectors and transformant cells with catalase genes cloned from microorganisms using genetic engineering technology, and obtaining the expression product. The invention also provides a novel recombinant plasmid and a novel transformant cell constructed in the process.In addition, the invention provides a composition for decomposing hydrogen peroxide contained in the residual disinfectant on contact lenses, which comprising the novel catalase of the invention.

Abstract: Disclosed is a mutant aspartase comprising the amino acid sequence of a wild-type E. coli aspartase wherein the amino acid residue at one of positions 25, 123, 421 and 463 is substituted. Also disclosed is a process for preparing the above mutant aspartase.

Abstract: A process for preparing optically active allylic alcohol derivatives comprises reacting a racemic mixture of the following formula I ##STR1## wherein R is alkyl, alkenyl, or substituted or unsubstituted aryl or arylalkyl;with acetate or anhydride under the catalysis of Pseudomonase AK, PS or K-10 lipase in the presence of an organic solvent.

Abstract: A compound of formula I, ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.1 ', R.sub.2 ', and R.sub.3 ' are independently the same or different and each represent hydrogen, hydroxy, or lower alkoxy, or any vicinal two of R.sub.1, R.sub.2, R.sub.3, R.sub.1 ', R.sub.2 ', and R.sub.3 ' combined together represent --O--(CH.sub.2).sub.n --O--, wherein n=1 or 2; R.sub.4 represents methylene or halomethyl; and X.sub.1, X.sub.2, X.sub.3, and X.sub.4 are independently the same or different and each represent hydrogen or halogen; or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition that contains an effective amount of a compound of formula I together with a pharmaceutically acceptable excipient, and a method of treating cancer that involves the administration of an effective amount of the compound of formula I to a patient in need thereof.

Abstract: A compound of the formula: ##STR1## wherein X is arylene, heteroarylene, fused arylene, fused heteroarylene, or deleted; Y is sulfonyl, --O--, or deleted; R.sub.1 is aryl, heteroaryl, fused aryl, or fused heteroaryl; R.sub.2 is H, lower alkyl, lower alkoxy, halo, nitro, cyano, haloalkyl, hydroxyl, carboxyl, amido, amino, or aminoalkyl; or a salt thereof are disclosed. Also disclosed are a pharmaceutical composition which contains an excipient and an effective amount of a compound of the above formula and a method of treating cancer which involves the administration of an effective amount of such a compound to a patient in need thereof.

Abstract: A stable solid dispersion of prostaglandin drug, particularly Misoprostol, (.+-.)methyl 7-?3(.alpha.)-hydroxy-2-.beta.-(4 (RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-oxycyclopent-1.alpha.-yl!hepta noate, comprising ammonio methacrylate copolymers. The ammonio methacrylate copolymers comprise Eudragit RS series, Eudragit RL series, Eudragit S, Eudragit L, and the mixture thereof. The stable solid dispersion is a sustained release type.

Abstract: A process for obtaining trehalose by growing a fungus of the genus Pleurotus in a liquid or solid medium and purifying the trehalose produced by the fungus.

Abstract: Nucleotide sequences of two circular single-stranded DNAs associated with Banana Bunchy Top Virus and the proteins encoded by the open reading frames in the nucleotide sequences are provided. A method for detecting Banana Bunchy Top Virus using the PCR technique based on the nucleotide sequences is also provided.

Abstract: The invention relates to novel compounds of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, hydroxy or alkoxy;R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be hydrogen or alkyl; andn is 0,1 or 2;and the pharmaceutically acceptable salts thereof.The invention also relates to the processes for preparing the compounds of formula (I), and the pharmaceutical compositions containing them, and their use as a low density lipoprotein peroxidation inhibitors, anti-atherosclerotic agents and/or antihyperlipidemic agents.

Abstract: The invention relates to compounds of formula (I) ##STR1## wherein R.sup.1 is an optional substituent any position of phenyl ring and is selected from halogen, --NO.sub.2, --NH.sub.2, --OH and --O--CR.sub.1-6 alkyl;--CH.sub.2 R.sup.2 is a substituent at 1- or 3- position of 1,2,3,4-tetrahydroisoquinoline, whereinR.sup.2 is an azole group such as imidazole or triazole; andR.sup.3 is phenyl optionally substituted with one or more halogen,and pharmaceutical salts thereof.The compounds of formula (I) and salts thereof are useful as antifungal agents.The invention also relates to the antifungal pharmaceutical compositions containing the compounds of formula (I), the methods of treating fungal infections using the compounds of formula (I) and the process for preparing the compounds of formula (I).

Abstract: Disclosed are new fluorogenic substrates for assay of angiotensin converting enzyme, a process for preparing them and methods for using them to assay angiotensin converting enzyme and to screen antihypertensive agents which inhibit angiotensin converting enzyme.

Abstract: A process for preparing fluconazole, including the steps of (1) acylating 1,3-difluorobenzene (DFB) to obtain 2-chloro-2',4'-difluoroacetophenone (CAP); (2) alkylating 4-amino-4H-1,2,4-triazole (4-AT) with CAP to obtain 2-(1H-1,2,4-triazol-1-yl)-2',4'-difluoroacetophenone (TAAP) salt; (3) deaminating TAAP salt to obtain TAAP; and (4) reacting TAAP with 1,2,4-triazole to obtain fluconazole.

Abstract: Disclosed is an automatic computer-controlled bioreactor system for enzymatic synthesis of L-tryptophan which comprises a bioreactor linked to a computer equipped with an on-line indole assay device, in which the computer controls the feeding of indole, pyruvic acid and/or its salt and an ammonium salt into the bioreactor and feedback-controls the reaction in the bioreactor by indole concentration determined by the on-line indole assay device, wherein the feeding of indole and ammonium salt is controlled by a pre-defined profile that agrees with a tryptophanase activity profile and pyruvic acid and/or its salt is added at a predetermined time.

Abstract: A process of preparing 2-cyano-3,5-dimethyl-4-methoxypyridine. The process includes the steps of: acylating 2-methyl-1-penten-1-alkoxy-3-one to obtain 2-alkoxycarbonyl-3,5-dimethyl-4-pyrone; ammonolyzing 2-alkoxycarbonyl-3,5-dimethyl-4-pyrone to obtain 2-carboxamido-3,5-dimethyl-4(1H)-pyridone; methylating 2-carboxamido-3,5-dimethyl-4(1H)-pyridone to obtain 2-carboxamido-3,5-dimethyl-4-methoxypyridine; and dehydrating said 2-carboxamido-3,5-dimethyl-4-methoxypyridone to obtain 2-cyano-3,5-dimethyl-4-methoxypyridine.